Managing Lipid Therapy

Documents to Request

• Fasting lipid panel (recent, within 4–12 weeks of assessment)
• Prior lipid panels for trend analysis
• 10-year ASCVD risk score calculation
• CAC score report if obtained
• Current medication list
• History of statin intolerance documentation
• Lp(a) level if available
• hsCRP if available
• HbA1c (diabetes status)
• Hepatic function panel (baseline before statin initiation)

Step 1: Patient Risk Category Classification

2018 ACC/AHA Risk Groups:

10-Year ASCVD Risk Thresholds (Primary Prevention):

Risk-Enhancing Factors (tip the balance toward statin initiation):

• Family history of premature ASCVD (♂ < 55, ♀ < 65)
• Persistently elevated LDL ≥ 160 mg/dL
• Metabolic syndrome
• CKD (eGFR 15–59)
• Chronic inflammatory conditions (RA, psoriasis, HIV)
• South Asian ancestry
• Premature menopause (< 40 years)
• Preeclampsia history
• Lp(a) ≥ 50 mg/dL (or ≥ 125 nmol/L)
• hsCRP ≥ 2.0 mg/L
• ABI < 0.9

Step 2: Statin Selection and Intensity

High-Intensity Statins (≥ 50% LDL reduction):

Moderate-Intensity Statins (30–49% LDL reduction):

Drug Interactions to Check:

• Simvastatin: contraindicated with strong CYP3A4 inhibitors (clarithromycin, itraconazole, HIV protease inhibitors); max 20 mg with amiodarone, amlodipine
• Atorvastatin: dose limit with cyclosporine, clarithromycin, itraconazole
• Rosuvastatin: preferred in patients on CYP3A4 inhibitors (metabolized by CYP2C9)
• All statins: caution with gemfibrozil (rhabdomyolysis risk)

Step 3: LDL-C Target Assessment and Escalation

LDL-C Targets by Risk Category:

Escalation Ladder (add sequentially if LDL not at target):

1. Maximize statin intensity (atorvastatin 80 mg or rosuvastatin 40 mg)
2. Add ezetimibe 10 mg (additional 15–20% LDL reduction; IMPROVE-IT trial)
3. Add PCSK9 inhibitor: evolocumab 140 mg SC q2 weeks or alirocumab 75–150 mg SC q2 weeks (additional 50–60% LDL reduction; FOURIER, ODYSSEY trials)
4. Consider bempedoic acid 180 mg daily (additional 15–18% LDL reduction; CLEAR Outcomes trial) — particularly useful in statin-intolerant patients
5. Consider inclisiran 284 mg SC (at months 0, 3, then q6 months) for sustained LDL lowering

Recheck lipid panel 4–12 weeks after any therapy change.

Step 4: Managing Statin Intolerance

True vs. Perceived Statin Intolerance:

• True myopathy: CK elevation > 10× ULN with symptoms → discontinue immediately
• Statin-associated muscle symptoms (SAMS): myalgia without significant CK elevation → most common reason for discontinuation

Approach to SAMS:

1. Hold statin for 2–4 weeks (washout)
2. Rechallenge with a different statin at low dose (rosuvastatin 5 mg or pravastatin 20 mg)
3. Try alternate-day dosing (rosuvastatin or atorvastatin — long half-lives permit this)
4. If intolerant to ≥ 2 statins: document as "statin-intolerant"
5. Use non-statin therapies: ezetimibe ± bempedoic acid ± PCSK9i

CoQ10 supplementation: Mixed evidence; may consider 100–200 mg daily if patient requests, but not a substitute for rechallenge strategy.

Step 5: Special Populations and Monitoring

Hypertriglyceridemia Management:

• TG 150–499 mg/dL: lifestyle + statin (treat ASCVD risk)
• TG ≥ 500 mg/dL: fibrate or omega-3 fatty acids (icosapent ethyl 4 g/day per REDUCE-IT) to prevent pancreatitis
• Icosapent ethyl (Vascepa): indicated for TG 135–499 with ASCVD or diabetes + ≥ 2 risk factors, on statin → 25% RRR for MACE

Monitoring Schedule:

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Is the patient correctly categorized by ASCVD risk group?
2. Is the statin intensity appropriate for the risk category?
3. Is the LDL-C at target, or is an escalation plan documented?
4. Are risk-enhancing factors documented for borderline/intermediate risk patients?
5. If statin intolerance is claimed, is the rechallenge protocol documented?

Quality Audit

• Fasting lipid panel documented with date
• 10-year ASCVD risk score calculated (for primary prevention patients)
• Risk category assigned per 2018 ACC/AHA guideline
• Statin intensity matches risk category
• LDL-C target identified and current level compared
• Escalation plan documented if LDL not at target
• Drug interactions checked for statin selection
• Risk-enhancing factors assessed for borderline/intermediate risk
• CAC scoring considered for shared decision-making in intermediate risk
• Statin intolerance properly documented with rechallenge history
• Hypertriglyceridemia assessed and treated if TG ≥ 500
• Icosapent ethyl considered for eligible patients (REDUCE-IT criteria)
• Follow-up lipid panel scheduled at appropriate interval
• Lifestyle modifications (diet, exercise, weight) reinforced

Guidelines

1. Every ASCVD patient should be on high-intensity statin therapy unless contraindicated — this is the single most impactful pharmacotherapy for secondary prevention.
2. Do not use LDL-C thresholds as the sole criterion for initiating statins in primary prevention — the 10-year ASCVD risk score drives the decision.
3. For patients with LDL ≥ 190 mg/dL, start high-intensity statin without risk calculation — this likely represents familial hypercholesterolemia.
4. CAC score of 0 in intermediate-risk patients supports deferring statin therapy (low event rate) — but does not apply to patients with diabetes, ASCVD, or LDL ≥ 190.
5. PCSK9 inhibitors provide large LDL reductions but should be reserved for patients who cannot reach target on maximally tolerated statin + ezetimibe — document prior authorization requirements.
6. Statin intolerance requires objective documentation: ≥ 2 statin trials, symptom recurrence with rechallenge, and symptom resolution with discontinuation. Nocebo effect is common.
7. Routine CK monitoring in asymptomatic patients on statins is not recommended — check only if muscle symptoms develop.
8. Omega-3 fish oil supplements (non-prescription) do not have cardiovascular benefit at standard doses — only icosapent ethyl 4 g/day (prescription EPA) has trial-proven benefit.